Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected south African patients

被引:43
|
作者
Selabe, S. Gloria
Lukhwareni, Azwidowi
Song, Ernest
Leeuw, Yeegan G. M.
Burnett, Rosemary J.
Mphahlele, M. Jeffrey
机构
[1] Univ Limpopo, Dept Virol, HIV & Hepatitis Res Unit, Pretoria, South Africa
[2] Johannesburg Hosp, Hepatol Div, Dept Med, Johannesburg, South Africa
[3] Univ Witwatersrand, Johannesburg, South Africa
[4] Margarita Hlth Ctr, Pretoria, South Africa
关键词
lamivudine-resistant HBV strains; hepatitis B virus; human immunodeficiency virus; HBV-HIV coinfection; sub-Saharan Africa;
D O I
10.1002/jmv.20974
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This was an exploratory study to investigate larnivudine-resistant hepatitis 13 virus (HBV) strains in selected lamivudine-naive HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients. Thirty-five lamivudine-naive HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HlV co-infected patients. The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg-positive) patients. HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL). Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor((R)) test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients. To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-naive HBV-HIV co-infected patients. The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and < 200 to 4.40 x 10(3) copies/ml, respectively. It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
引用
收藏
页码:1650 / 1654
页数:5
相关论文
共 50 条
  • [21] High Frequency of Lamivudine Resistance Mutations in Brazilian Patients Co-Infected With HIV and Hepatitis B
    Mendes-Correa, M. C.
    Pinho, J. R. R.
    Locarnini, S.
    Yuen, L.
    Sitnik, R.
    Santana, R. A. F.
    Gomes-Gouvea, M. S.
    Leite, O. M.
    Martins, L. G.
    Silva, M. H.
    Gianini, R. J.
    Uip, D. E.
    JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (09) : 1481 - 1488
  • [22] Hepatitis B virus genetic multiplicity and the associated HBV lamivudine resistance mutations in HBV/HIV co-infection in Western Kenya: A review article
    Wandera, Bernard Onyango
    Onyango, David Miruka
    Musyoki, Stanslaus Kiilu
    INFECTION GENETICS AND EVOLUTION, 2022, 98
  • [23] Entecavir plus lamivudine as an alternative treatment for co-infected HBV/HIV patients with toxicity on tenofovir therapy
    Fontecha-Ortega, Maria
    Munoz-Mendoza, Vanesa
    Monsalvo, Marta
    Mateos, Marisa
    Angel Rodriguez-Sagrado, Miguel
    Gomez, Cristina
    Luis Casado, Jose
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [24] Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals
    Cooley, L
    Ayres, A
    Bartholomeusz, A
    Lewin, S
    Crowe, S
    Mijch, A
    Locarnini, S
    Sasadeusz, J
    AIDS, 2003, 17 (11) : 1649 - 1657
  • [25] HBV transcription and translation persist despite viral suppression in HBV-HIV co-infected patients on antiretroviral therapy
    Lisker-Melman, Mauricio
    Wahed, Abdus S.
    Ghany, Marc G.
    Chung, Raymond T.
    King, Wendy C.
    Kleiner, David E.
    Bhan, Atul K.
    Khalili, Mandana
    Jain, Mamta K.
    Sulkowski, Mark
    Wong, David K.
    Cloherty, Gavin
    Sterling, Richard K.
    HEPATOLOGY, 2023, 77 (02) : 594 - 605
  • [26] Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China
    He Yaozu
    Lin Weiyin
    Li Hong
    Gu Fei
    Zhong Huolin
    Lan Yun
    Li Yonghong
    Guo Pengle
    Hu Fengyu
    Cai Weiping
    Tang Xiaoping
    Li Linghua
    中华医学杂志英文版, 2023, 136 (22)
  • [27] Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China
    He, Yaozu
    Lin, Weiyin
    Li, Hong
    Gu, Fei
    Zhong, Huolin
    Lan, Yun
    Li, Yonghong
    Guo, Pengle
    Hu, Fengyu
    Cai, Weiping
    Tang, Xiaoping
    Li, Linghua
    CHINESE MEDICAL JOURNAL, 2023, 136 (22) : 2686 - 2693
  • [28] Baseline characteristics of HIV & hepatitis B virus (HIV/HBV) co-infected patients from Kolkata, India
    Sarkar, Jayeeta
    Saha, Debraj
    Bandyopadhyay, Bhaswati
    Saha, Bibhuti
    Kedia, Deepika
    Mazumder, D. N. Guha
    Chakravarty, Runu
    Guha, Subhasish Kamal
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2016, 143 : 636 - 642
  • [29] HBV/HIV co-infection: The dynamics of HBV in South African patients with AIDS
    Mayaphi, Simnikiwe H.
    Rossouw, Theresa M.
    Masemola, Difuro P.
    Olorunju, Steve A. S.
    Mphahlele, M. Jeffrey
    Martin, Desmond J.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2012, 102 (03): : 157 - 162
  • [30] Wild type and YMDD variant of hepatitis B virus: No difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients
    de Vries-Sluijs, TEMS
    van der Eijk, AA
    Hansen, BE
    Osterhaus, ADME
    de Man, RA
    van der Ende, ME
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 (01) : 60 - 63